23 November 2017
: Case report
Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction
Simone M. Mrotzek1ABCDE, Tienush Rassaf1AEF, Matthias Totzeck1ABEF*DOI: 10.12659/AJCR.905974
Am J Case Rep 2017; 18:1238-1241
Abstract
BACKGROUND: Following acute coronary intervention in cardiology patients, the combined medical therapy with the platelet inhibitory drug ticagrelor and a statin medication (e.g., simvastatin) is recommended according to international guidelines. Yet combined therapeutic regimens have the potential of pharmacological interaction with both ticagrelor and simvastatin being metabolized by CYP3A4. Rhabdomyolysis is a known side-effect of statin therapy and combined therapy increases the susceptibility to this complication.
CASE REPORT: A 72-year-old patient presented to our Emergency Department with typical signs of rhabdomyolysis consisting of muscular cramps and pain in both legs and a significant elevation of creatinine kinase (CK). Five months prior to this presentation, he had been hospitalized due to acute coronary syndrome followed by a coronary intervention of a high-grade left anterior descending artery stenosis. His long-term medication included simvastatin 20 mg daily, which he had taken for several years, and ticagrelor, which had been added to his medication following coronary intervention. The patient showed fast recovery of symptoms and rapid normalization of CK levels upon treatment change from ticagrelor to clopidogrel with a paused statin administration.
CONCLUSIONS: The combined use of ticagrelor with low dose simvastatin poses a risk for rhabdomyolysis even in patients with normal kidney function. Patients treated with ticagrelor might require changes in statin therapy and dose adjustments in order to avoid pharmacological interactions and higher risk for adverse effects.
Keywords: acute coronary syndrome, Angiostatins, rhabdomyolysis
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946614
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946488
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946876
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946560
Most Viewed Current Articles
21 Jun 2024 : Case report
96,182
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,159
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
31,026
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,365
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030